Chu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chu Zhang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Can Cui
Jiangsu Key Laboratory of Brain Disease and Bioinformation, Xuzhou Medical University, Xuzhou, China
1 shared publication- Can Cui
Jiangsu Key Laboratory of Brain Disease and Bioinformation, Xuzhou Medical University, Xuzhou, China
1 shared publication - Can Gao
NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, Jiangsu Province Key Laboratory of Anesthesiology, Jiangsu Province Key Laboratory of Anesthesia and Analgesia Application, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China
1 shared publication Chuanying Xu
Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
1 shared publication- Guiyun Cui
Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
1 shared publication Hailong Lu
Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
1 shared publication
Latest Publications
- 17 August 2026
- Published by Springer Nature in Brain Structure and Function
- Vol. 231 (7) , 121
Predicting big five personality traits from resting-state EEG connectivity: a connectome predictive modeling study
- 17 August 2026
- Published by Springer Nature in Brain Structure and Function
- Vol. 231 (7) , 121
Predicting big five personality traits from resting-state EEG connectivity: a connectome predictive modeling study
- Open Access
- 8 December 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Classifying the risk of cognitive impairment in Parkinson’s disease using serum bile acid profiles and machine learning
Cognitive impairment (CI) is a common and early non-motor manifestation of Parkinson’s disease (PD), yet its biochemical basis remains poorly understood. Given the emerging link between bile acids (BAs) and neurodegeneration, we investigated whether serum BA profiles differ by cognitive status in PD and whether they can classify CI. A total of 363 participants were enrolled, including 63 healthy controls, 154 PD patients with normal cognition, and 146 with CI. Serum BA concentrations were quantified by ultra-performance liquid chromatography–tandem mass spectrometry, and multivariate as well as machine learning analyses were applied. Compared with cognitively normal PD patients, those with CI exhibited distinct BA alterations, characterized by elevated deoxycholic and cholic acids and reduced glyco- and tauro-conjugated species. Deoxycholic acid showed the strongest negative correlations with cognitive scores. Machine learning models based on combined BA profiles, particularly the random forest classifier, achieved robust discrimination between PD-CI and PD-NC groups (AUC up to 0.90). These findings indicate that BA dysregulation is closely linked to cognitive impairment in PD and may serve as a promising metabolic biomarker for early detection. Clinical trial number. Not applicable.
- 8 December 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 12 (1)
Open AccessClassifying the risk of cognitive impairment in Parkinson’s disease using serum bile acid profiles and machine learning
Cognitive impairment (CI) is a common and early non-motor manifestation of Parkinson’s disease (PD), yet its biochemical basis remains poorly understood. Given the emerging link between bile acids (BAs) and neurodegeneration, we investigated whether serum BA profiles differ by cognitive status in PD and whether they can classify CI. A total of 363 participants were enrolled, including 63 healthy controls, 154 PD patients with normal cognition, and 146 with CI. Serum BA concentrations were quantified by ultra-performance liquid chromatography–tandem mass spectrometry, and multivariate as well as machine learning analyses were applied. Compared with cognitively normal PD patients, those with CI exhibited distinct BA alterations, characterized by elevated deoxycholic and cholic acids and reduced glyco- and tauro-conjugated species. Deoxycholic acid showed the strongest negative correlations with cognitive scores. Machine learning models based on combined BA profiles, particularly the random forest classifier, achieved robust discrimination between PD-CI and PD-NC groups (AUC up to 0.90). These findings indicate that BA dysregulation is closely linked to cognitive impairment in PD and may serve as a promising metabolic biomarker for early detection. Clinical trial number. Not applicable.